What it means for patients, drugmakers and prices
President Trump has proposed significant tariffs on imported generic medicines to encourage domestic manufacturing. The generic drug industry warns that structural challenges, such as reimbursement issues, may hinder this transition despite the proposed timeline.
Why it matters
This policy could fundamentally alter the pharmaceutical supply chain and impact the affordability and availability of essential generic medications for U.S. patients.
President Donald Trump 's proposed tariffs on imported generic medicines have raised fresh questions about whether low-cost drugmakers can shift production to the U.S. before duties of as much as 200% take effect.
Trump said Tuesday that imported generic medicines would face no tariffs for two years before duties rise to 100% for one year and then 200%, giving manufacturers time to invest in U.S. production.
The proposal targets a growing global industry, currently worth nearly $500 billion.
While the administration says tariffs will help bring pharmaceutical manufacturing back to the U.S., the generic drug industry argues that longstanding structural challenges, not just trade policy, limit domestic production.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in